Medicines: Oncology Portfolio and Pipeline

Home / Our therapy areas / Oncology / Medicines: Oncology Portfolio and Pipeline


At AstraZeneca, we aim to revolutionise cancer care with our portfolio, our pipeline and our people. We follow the science, wherever it takes us, in pursuit of the best medicines. Through this relentless quest for innovation, we have created one of the most diverse portfolios and pipelines in the industry - encompassing molecules and modalities designed to preferentially kill cancer cells, at every stage of disease.


Key disease areas

We are striving to make cure a reality for the millions of people across the world living with cancer every day. Our focus is on some of the most hostile and hard-to-treat cancers including pancreatic cancer, certain blood cancers, and cancers within breast, lung, ovarian, and prostate. By understanding the complexities of these cancer types, we can truly achieve life-changing benefits for patients.

We are balancing our focus on our industry-leading pipeline with the active life-cycle management of our existing medicines; expanding indications and exploring novel treatment combinations, to deliver to those patients with the greatest unmet need. Patients are always front of mind in everything we do – from the treatment options we provide and the daily impact these treatments can have.



Our scientific platforms

At AstraZeneca, our advances across our six scientific platforms have helped to improve patient outcomes. Further developments in epigenetics and across cell, gene and combination therapy hold the promise of new possibilities.

Our Oncology medicines

Our medicines at AstraZeneca are approved in individual countries for specific uses, and the information we provide for patients is governed by local regulations. In some countries, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. However, please note that in some countries we are not permitted to provide very much, or sometimes any, information on our prescription medicines, so you should only obtain information from trustworthy sources, and always ask a healthcare professional for advice about medicines.



Arimidex 

anastrozole

Calquence

acalabrutinib

Casodex, Cosudex

bicalutamide

Enhertu

trastuzumab deruxtecan

Faslodex 

fulvestrant

Imfinzi

durvalumab

Iressa

gefitinib

Koselugo

selumetinib

Lynparza

olaparib

Tagrisso

osimertinib

Zoladex

goserelin acetate implant


Our Oncology pipeline


At AstraZeneca our industry-leading pipeline includes investigational therapies in various stages of clinical development - from approved medicines to earlier-stage molecules in clinical trials.

Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III or have been submitted for regulatory approval and may include assets that are launched in one or more major markets (removed when launched in all applicable major markets).


Oncology (as of 29 April 2022)

Phase I

Phase I

  • AZD0466 haematological malignancies
  • AZD1390 glioblastoma
  • AZD2936 solid tumours
  • AZD5991 haematological malignancies
  • AZD7648 solid tumours
  • AZD7789 solid tumours, haematological malignancies
  • AZD8205 solid tumours
  • AZD8701 +/- Imfinzi solid tumours
  • Imfinzi + adavosertib solid tumours
  • IPH5201 solid tumours
  • MEDI1191 solid tumours
  • MEDI5752 + Lenvatinib advanced renal cell carcinoma
  • MEDI9253 solid tumours
  • Tagrisso + (Koselugo or savolitinib) TATTON advanced EGFRm non-small cell lung cancer

Phase II

Phase II

  • adavosertib ovarian cancer, solid tumours, uterine serous cancer
  • AZD0171 + Imfinzi + CTx 1st-line metastatic pancreatic ductal adenocarcinoma
  • AZD4573 haematological malignancies
  • AZD4573 + Calquence haematological malignancies
  • AZD5305 solid tumours
  • camizestrant oestrogen receptor +ve breast cancer
  • capivasertib prostate cancer
  • ceralasertib solid tumours
  • Imfinzi (platform) COAST non-small cell lung cancer
  • Imfinzi (platform) HUDSON post IO non-small cell lung cancer
  • Imfinzi (platform) NeoCOAST non-small cell lung cancer
  • Imfinzi + Lynparza ORION 1st-line metastatic non-small cell lung cancer
  • Imfinzi + monalizumab solid tumours
  • MEDI5752 solid tumours
  • oleclumab+CTx or Imfinzi+oleclumab+CTx metastatic pancreatic cancer
  • Tagrisso + savolitinib SAVANNAH advanced EGFRm non-small cell lung cancer

Phase III

Phase III

  • camizestrant + CDK4/6i SERENA-6 1st-line HR+ HER2- ESR1m breast cancer
  • camizestrant + palbociclib SERENA-4 1st-line HR+ HER2- breast cancer
  • capivasertib + abiraterone CAPItello-281 PTEN deficient metastatic hormone sensitive prostate cancer
  • capivasertib + CTx CAPItello-290 1st-line metastatic triple negative breast cancer
  • capivasertib + fulvestrant + palbociclib CAPItello-292 1st-line triplet in early relapse/ET resistant locally advanced (inoperable) or metastatic breast cancer
  • capivasertib + fulvestrant CAPItello-291 2nd-line and beyond in AI resistant locally advanced (inoperable) or metastatic breast cancer
  • datopotamab deruxtecan TROPION-Breast01 2-3L HR+ HER2- breast cancer
  • datopotamab deruxtecan TROPION-Lung01 2L+ NSCLC without actionable genomic mutations
  • Imfinzi + treme + TACE +/- Lenvatinib EMERALD-3 locoregional hepatocellular carcinoma
  • Imfinzi + tremelimumab + SoC NILE 1st-line urothelial cancer
  • Imfinzi + tremelimumab HIMALAYA 1st-line hepatocellular carcinoma
  • Imfinzi +/- tremelimumab + CRT ADRIATIC 1st-line limited-stage small-cell lung cancer
  • Imfinzi +/- tremelimumab + CTx POSEIDON 1st-line non-small cell lung cancer
  • Lynparza + Imfinzi + bevacizumab DUO-O 1st-line ovarian cancer
  • Lynparza + Imfinzi DUO-E 1st-line endometrial cancer
  • monalizumab + cetuximab INTERLINK-1 2L+ relapsed metastatic head and neck squamous cell cancer
  • savolitinib + Imfinzi SAMETA 1st-line papillary renal cell carcinoma

LCM Projects

LCM Projects

  • Calquence + R-CHOP ESCALADE 1st-line diffuse large B cell lymphoma
  • Calquence + venetoclax + obinutuzumab AMPLIFY 1st-line chronic lymphocytic leukaemia
  • Calquence ASCEND relapsed/refractory chronic lymphocytic leukaemia
  • Calquence ECHO 1st-line mantle cell lymphoma
  • Calquence ELEVATE-TN 1st-line chronic lymphocytic leukaemia
  • Enhertu (platform) DESTINY-Breast07 HER2+ breast cancer
  • Enhertu (platform) DESTINY-Breast08 HER2-low breast cancer
  • Enhertu DESTINY-Breast02 HER2-positive, unresectable and/or metastatic breast cancer pretreated with prior standard of care HER2 therapies, including T-DM1
  • Enhertu DESTINY-Breast03 HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane
  • Enhertu DESTINY-Breast04 HER2-low, unresectable and/or metastatic breast cancer subjects
  • Enhertu DESTINY-Breast05 HER2-positive post-neoadjuvant high-risk breast cancer
  • Enhertu DESTINY-Breast06 post-ET HER2-low/HR+ breast cancer 2L
  • Enhertu DESTINY-Breast09 1st-line HER2-positive breast cancer
  • Enhertu DESTINY-Breast11 Neoadjuvant HER2-positive breast cancer
  • Enhertu DESTINY-Gastric01 HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens
  • Enhertu DESTINY-Gastric04 2nd-line HER2-positive gastric
  • Enhertu DESTINY-Lung01 HER2-over-expressing or -mutated, unresectable and/or metastatic non-small cell lung cancer
  • Enhertu DESTINY-Lung04 1st-line HER2m non-small cell lung cancer
  • Enhertu DESTINY-PanTumour01 HER2 mutant tumours
  • Enhertu DESTINY-PanTumour02 HER2-expressing solid tumours
  • Imfinzi PEARL 1st-line metastatic non-small cell lung cancer
  • Imfinzi (platform) BEGONIA 1st-line metastatic triple negative breast cancer
  • Imfinzi (platform) MAGELLAN 1st-line metastatic non-small cell lung cancer
  • Imfinzi + CRT KUNLUN locally advanced oesophageal squamous cell carcinoma
  • Imfinzi + CRT PACIFIC-2 locally-advanced (stage III) non-small cell lung cancer
  • Imfinzi + CRT PACIFIC-5 (China) locally-advanced (stage III) non-small cell lung cancer
  • Imfinzi + CTx MERMAID-1 stage II-III adjuvant non-small cell lung cancer
  • Imfinzi + CTx neoadjuvant AEGEAN locally-advanced (stage II-III) non-small cell lung cancer
  • Imfinzi + CTx NIAGARA muscle invasive bladder cancer
  • Imfinzi + CTx TOPAZ-1 1st-line biliary tract cancer
  • Imfinzi + domvanalimab (AB154) + CTx PACIFIC-8 unresectable stage III non-small cell lung cancer
  • Imfinzi + EV +/- treme VOLGA muscle invasive bladder cancer
  • Imfinzi + FLOT MATTERHORN Neo-adjuvant/adjuvant gastric cancer
  • Imfinzi + VEGF + TACE EMERALD-1 locoregional hepatocellular carcinoma
  • Imfinzi + VEGF EMERALD-2 adjuvant hepatocellular carcinoma
  • Imfinzi +- oleclumab +- mona unresectable stage III NSCLC PACIFIC-9 NSCLC
  • Imfinzi MERMAID-2 stage II-III premetastatic non-small cell lung cancer
  • Imfinzi post-SBRT PACIFIC-4 stage I/II non-small cell lung cancer
  • Imfinzi POTOMAC non muscle invasive bladder cancer
  • Lynparza (basket) MK-7339-002 / LYNK002 HRRm cancer
  • Lynparza + abiraterone PROpel prostate cancer
  • Lynparza LYNK-003 platinum sensitive 1st-line colorectal cancer
  • Lynparza MONO-OLA1 1st-line BRCAwt ovarian cancer
  • Lynparza OlympiA gBRCA adjuvant breast cancer
  • Tagrisso + CTx FLAURA2 1st-line advanced EGFRm non-small cell lung cancer
  • Tagrisso +/- CTx neoadjuvant NeoADAURA stage II/III resectable EGFRm NSCLC
  • Tagrisso ADAURA adjuvant EGFRm non-small cell lung cancer
  • Tagrisso LAURA stage III EGFRm non-small cell lung cancer
  • Tagrisso ORCHARD platform study 2nd-line EGFRm osimertinib-resistant NSCLC

Collaboration in Oncology


Despite huge advances in cancer care over recent decades, at AstraZeneca, we know there is still more to be achieved. We cannot do this alone; we know that outsmarting cancer requires a collective and collaborative approach. From drug discovery collaborations to commercial partnerships, we are sourcing new medicines, investing in the brightest minds and funding research across the globe, with a focus on maximising impact through shared knowledge and experience.


Explore our Oncology pillars


Veeva ID: Z4-40328
Date of preparation: November 2021